28,600 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Bought by Dauntless Investment Group LLC

Key Points

• Dauntless Investment Group LLC acquired 28,600 shares of Stoke Therapeutics, Inc. during the first quarter, valued at approximately $190,000, representing a 0.05% stake in the company.
• Insider Barry Ticho sold 6,471 shares of Stoke Therapeutics for a total of $64,904.13, decreasing their position in the company by 20.06%.
• Several analysts have rated Stoke Therapeutics as a "buy" or "strong-buy," with a range of price targets suggesting significant upside potential from the current levels, with an average target of $25.80.

Dauntless Investment Group LLC bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 28,600 shares of the company's stock, valued at approximately $190,000. Dauntless Investment Group LLC owned 0.05% of Stoke Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of STOK. GAMMA Investing LLC increased its position in Stoke Therapeutics by 1,842.0% during the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after acquiring an additional 5,084 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Stoke Therapeutics in the 4th quarter worth approximately $63,000. Teacher Retirement System of Texas bought a new stake in shares of Stoke Therapeutics in the 4th quarter worth approximately $113,000. Tower Research Capital LLC TRC lifted its position in shares of Stoke Therapeutics by 70.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock worth $132,000 after acquiring an additional 4,918 shares during the period. Finally, Invesco Ltd. bought a new stake in shares of Stoke Therapeutics in the 4th quarter worth approximately $133,000.

Insider Activity at Stoke Therapeutics

In other news, insider Barry Ticho sold 6,471 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total value of $64,904.13. Following the sale, the insider owned 25,782 shares in the company, valued at approximately $258,593.46. The trade was a 20.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 9.50% of the company's stock.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK opened at $12.81 on Tuesday. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $16.15. The company's fifty day moving average is $11.43 and its 200-day moving average is $9.75. The company has a market capitalization of $699.43 million, a PE ratio of 16.22 and a beta of 1.14.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Jefferies Financial Group assumed coverage on shares of Stoke Therapeutics in a report on Friday, July 18th. They issued a "buy" rating and a $30.00 price target on the stock. Finally, HC Wainwright lowered their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Stoke Therapeutics presently has an average rating of "Buy" and an average price target of $25.80.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.